Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

A Comparison of Two Urinary Catheters of Different Lengths for Female Use, in Intermittent Catheterization

26 de abril de 2021 atualizado por: Wellspect HealthCare

A Multi Centre, Single-blind, Randomized, Cross-over Study Comparing Two Female Catheters With Different Length in Terms of Residual Urine After Intermittent Catheterization

A study comparing a 10 cm catheter with a 7 cm catheter in a group of female patients who, on a routine bases, empty their bladder using urinary catheters, by measuring residual urine after intermittent catheterization.

Visão geral do estudo

Status

Concluído

Condições

Descrição detalhada

The study personnel will conduct three bladder scans after each catheterization in order to obtain the mean residual urine volume. Each patient will catheterize herself two times with each product, i.e. a total of four catheterizations.

Diagnosis and BMI will be collected at visit 1 to assess whether the residual urine volume differs between these subgroups.

The hypothesis that the mean residual volumes were equal when using the 7 and the 10 centimeter catheters was tested by means of the Wilcoxon signed rank test.

Tipo de estudo

Intervencional

Inscrição (Real)

60

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Borås, Suécia, SE-501 82
        • Rehabiliteringskliniken, Södra Älvsborgs Sjukhus
      • Gothenburg, Suécia, SE-413 45
        • Verksamhet Urologi, Sahlgrenska Universitetssjukhuset
      • Lund, Suécia, SE-221 85
        • Clinical Research and Trial Centre, Lund University Hospital

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Inclusion Criteria:

  • Provision of signed informed consent
  • Female subjects aged 18 years and over
  • Experienced users of CIC with a minimum of one month of use
  • Practice CIC a minimum of 1 time per day
  • Practice CIC with female catheters with a maximum length of 20 cm
  • Perform self-catheterization
  • Sufficient hand function to be able to open and handle catheter packages
  • Use catheters with Ch 10, 12 or 14

Exclusion Criteria:

  • Pregnancy
  • Ongoing symptomatic UTI
  • Involvement in the planning and conduct of the study (applies to both Astra Tech staff or staff at the study site)
  • Previous enrolment or randomisation of treatment in the present study
  • Participation in another clinical study during the study period
  • Severe non-compliance to protocol as judged by the investigator and/or Astra Tech

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Outro
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição cruzada
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: AABB

A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 7 cm then 7 cm then 10 cm then 10 cm

Four catheterizations in total, two catheterizations with each study product in a randomized order.

Catheterization should resemble the daily use as far as possible and at least 2 hours had to pass between 2 catheterizations.The study centre decided whether the subject performed all four catheterizations on one or several days.
Outros nomes:
  • Coloplast SpeediCath Compact 7 cm
  • Astra Tech POBE 10 cm
Experimental: ABAB

A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 7 cm then 10 cm then 7 cm then 10 cm

Four catheterizations in total, two catheterizations with each study product in a randomized order.

Catheterization should resemble the daily use as far as possible and at least 2 hours had to pass between 2 catheterizations.The study centre decided whether the subject performed all four catheterizations on one or several days.
Outros nomes:
  • Coloplast SpeediCath Compact 7 cm
  • Astra Tech POBE 10 cm
Experimental: ABBA

A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 7 cm then 10 cm then 10 cm then 7 cm

Four catheterizations in total, two catheterizations with each study product in a randomized order.

Catheterization should resemble the daily use as far as possible and at least 2 hours had to pass between 2 catheterizations.The study centre decided whether the subject performed all four catheterizations on one or several days.
Outros nomes:
  • Coloplast SpeediCath Compact 7 cm
  • Astra Tech POBE 10 cm
Experimental: BAAB

A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 10 cm then 7 cm then 7 cm then 10 cm

Four catheterizations in total, two catheterizations with each study product in a randomized order.

Catheterization should resemble the daily use as far as possible and at least 2 hours had to pass between 2 catheterizations.The study centre decided whether the subject performed all four catheterizations on one or several days.
Outros nomes:
  • Coloplast SpeediCath Compact 7 cm
  • Astra Tech POBE 10 cm
Experimental: BABA

A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 10 cm then then 7 cm then 10 cm then 7 cm

Four catheterizations in total, two catheterizations with each study product in a randomized order.

Catheterization should resemble the daily use as far as possible and at least 2 hours had to pass between 2 catheterizations.The study centre decided whether the subject performed all four catheterizations on one or several days.
Outros nomes:
  • Coloplast SpeediCath Compact 7 cm
  • Astra Tech POBE 10 cm
Experimental: BBAA

A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 10 cm then 10 cm then 7 cm then 7 cm

Four catheterizations in total, two catheterizations with each study product in a randomized order.

Catheterization should resemble the daily use as far as possible and at least 2 hours had to pass between 2 catheterizations.The study centre decided whether the subject performed all four catheterizations on one or several days.
Outros nomes:
  • Coloplast SpeediCath Compact 7 cm
  • Astra Tech POBE 10 cm

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Bladder Scan Measurements of Residual Urine Volume
Prazo: Three bladder scan measurements were performed immediately after each catheterization and a mean value was calculated. A maximum of 5 minutes were allowed to elapse between catheterization and bladder scan.

Measurements were performed with the bladder scan BVI 3000. The primary outcome variable was average residual urine volume (mL) calculated from repetitive bladder scans performed after each catheterization.

Three bladder scan measurements were performed immediately after each catheterization and a mean value was calculated.

Three bladder scan measurements were performed immediately after each catheterization and a mean value was calculated. A maximum of 5 minutes were allowed to elapse between catheterization and bladder scan.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Number of Subjects With a Residual Volume >5mL or ≤5mL
Prazo: Three bladder scan measurements were performed immediately after each catheterization and a mean value was calculated. At least 2 hours had to pass between 2 catheterizations.
Three bladder scan measurements were performed immediately after each catheterization and a mean value was calculated. At least 2 hours had to pass between 2 catheterizations.
Number of Subjects With a Residual Volume >10mL or ≤10mL
Prazo: Three bladder scan measurements were performed immediately after each catheterization and a mean value was calculated. A maximum of 5 minutes were allowed to elapse between catheterization and bladder scan.
Three bladder scan measurements were performed immediately after each catheterization and a mean value was calculated. A maximum of 5 minutes were allowed to elapse between catheterization and bladder scan.
Number of Subjects With a Residual Volume >30mL or ≤30mL
Prazo: Three bladder scan measurements were performed immediately after each catheterization and a mean value was calculated. A maximum of 5 minutes were allowed to elapse between catheterization and bladder scan.
Three bladder scan measurements were performed immediately after each catheterization and a mean value was calculated. A maximum of 5 minutes were allowed to elapse between catheterization and bladder scan.
Number of Subjects With a Residual Volume >50mL or ≤50mL
Prazo: Three bladder scan measurements were performed immediately after each catheterization and a mean value was calculated. A maximum of 5 minutes were allowed to elapse between catheterization and bladder scan.
Three bladder scan measurements were performed immediately after each catheterization and a mean value was calculated. A maximum of 5 minutes were allowed to elapse between catheterization and bladder scan.
Does the Subject's Bladder Feel Completely Empty After Catheterisation (All Subjects)
Prazo: Question asked minutes after catheterization.

After each catheterization the study nurse will ask the subject whether it feels as if the bladder is completely emptied or not.

0=No and 1=Yes.

Question asked minutes after catheterization.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Ulf Malmqvist, MD, PhD, Assoc.Prof., Clinical Research and Trial Centre, Lund University Hospital

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de novembro de 2008

Conclusão Primária (Real)

1 de janeiro de 2009

Conclusão do estudo (Real)

1 de março de 2009

Datas de inscrição no estudo

Enviado pela primeira vez

28 de novembro de 2008

Enviado pela primeira vez que atendeu aos critérios de CQ

28 de novembro de 2008

Primeira postagem (Estimativa)

1 de dezembro de 2008

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de maio de 2021

Última atualização enviada que atendeu aos critérios de controle de qualidade

26 de abril de 2021

Última verificação

1 de abril de 2021

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • YA-LOF-0015

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever